市場調查報告書
商品編碼
1635964
2025-2033 年男性性腺功能減退症市場報告(依治療類型、藥物傳遞、應用和地區)Male Hypogonadism Market Report by Therapy Type, Drug Delivery, Application, and Region 2025-2033 |
2024年,全球男性性腺功能IMARC Group症市場規模達39億美元。男性睪固酮缺乏症盛行率的大幅上升、患者群體對男性性腺功能減退症治療選擇的認知不斷提高以及健康意識的增強是推動市場的一些關鍵因素。
男性性腺功能減退症是一種睪丸無法產生足夠睪固酮的疾病,導致肌肉生長不足、毛髮生長受損、乳房發育受損、聲音低沉。這種疾病的特徵是男性缺乏睪固酮或精子產生。它是由與睪丸(原發性性腺功能減退症)或下丘腦-腦下垂體軸(繼發性性腺功能減退症)相關的疾病引起的。性腺機能減退症患者可能會遭受各種器官功能障礙以及生活品質下降,因為它源自於影響下視丘和腦下垂體的睪丸問題或疾病。男性性腺功能減退症可能是遺傳性的,也可能是後天性的,由荷爾蒙失衡、藥物或老化引起。幾種先天性酵素異常會導致全身不同程度的雄性激素抵抗。性腺功能減退症最常見於 60 歲以上的男性,其症狀和適應症也相應不同。
全球市場的主要動力是男性睪固酮缺乏症盛行率大幅上升以及不孕率上升。這可歸因於慢性生活方式障礙(包括肥胖和糖尿病)的發生率不斷增加。與此一致的是,更容易患有男性性腺功能減退症的老年人口的不斷擴大也為市場提供了動力。此外,患者群體對男性性腺功能減退症治療選擇的認知不斷提高,也是一個重要的生長誘導因素。多個國家的政府機構正在提高人們對性腺功能減退症治療方法的認知,包括睪固酮替代療法(TST)。然而,與外部睪固酮激素注射相關的嚴重不良反應是男性性腺功能減退症市場的一個重要的成長限制因素。相反,臨床試驗數量的增加和新治療方案的出現預計將在預測期內創造新的男性性腺功能減退症市場成長機會。除此之外,全球醫療基礎設施發展的持續技術進步正在為市場創造積極的前景。促進市場發展的其他一些因素包括快速城市化、日益增強的健康意識、高額醫療支出和廣泛的研發(R&D)活動。
The global male hypogonadism market size reached USD 3.9 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 5.8 Billion by 2033, exhibiting a growth rate (CAGR) of 4.31% during 2025-2033. A considerable rise in the prevalence of testosterone deficiency in males, the rising awareness of male hypogonadism treatment choices among the patient population, and increasing health consciousness represent some of the key factors driving the market.
Male hypogonadism is a medical condition in which the testes fail to produce enough testosterone, leading to a lack of muscle growth, impaired hair growth, breast development, as well as a lack of deepening of the voice. The medical condition is characterized by a lack of testosterone or spermatozoa production in men. It is caused owing to the disorder related to the testes (primary hypogonadism) or the hypothalamic-pituitary axis (secondary hypogonadism). An individual with hypogonadism may suffer from a variety of organ dysfunctions as well as a reduction in quality of life since it originates from a testicular problem or disorder that affects the hypothalamus and pituitary gland. Hypogonadism in men can be genetic or acquired, caused by hormonal imbalances, medications or aging. Several congenital enzyme abnormalities are responsible for causing different degrees of androgen resistance throughout the body. Hypogonadism is most common in men over the age of 60, and the symptoms and indications of the deficiency vary accordingly.
The global market is primarily driven by a considerable rise in the prevalence of testosterone deficiency in males, along with the growing infertility rates. This can be attributed to the increasing incidences of chronic lifestyle disorders, including obesity and diabetes. In line with this, the expanding geriatric population that is more susceptible to developing male hypogonadism is also providing an impetus to the market. Moreover, the rising awareness of male hypogonadism treatment choices among the patient population is also acting as a significant growth-inducing factor. Government bodies across several countries are promoting awareness of hypogonadism treatment methods, including testosterone replacement therapy (TST). However, severe adverse reactions associated with external testosterone hormone injections are acting as a significant growth-restraining factor for the male hypogonadism market. Conversely, the increasing number of clinical trials and the emergence of new treatment options are expected to create new male hypogonadism market opportunities for growth during the forecast period. Apart from this, continual technological advancements in the development of medical infrastructure on the global level are creating a positive outlook for the market. Some of the other factors contributing to the market include rapid urbanization, increasing health consciousness, high medical expenditure and extensive research and development (R&D) activities.
Therapy Type Insights
Testosterone Replacement Therapy
Gonadotropin-Releasing Hormones Therapy
Drug Delivery Insights
Topical Gels
Injectables
Transdermal Patches
Others
Application Insights
Kallmann Syndrome
Klinefelters Syndrome
Pituitary Disorders
Others
Regional Insights
North America
United States
Canada
Asia Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The report has also provided a comprehensive analysis of all the major regional markets that include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and Middle East and Africa. According to the report, North America was the largest market for male hypogonadism. Some of the factors driving the North America male hypogonadism market include the growing geriatric population, rising prevalence of sedentary lifestyle and related medical conditions, increasing number of clinical trials, the emergence of new treatment options, etc.
The report has also provided a comprehensive analysis of the competitive landscape in the global male hypogonadism market. Detailed profiles of all major companies have also been provided. Some of the companies covered include AbbVie Inc, Endo International Plc, Ferring Holding S.A, Grunenthal GmbH, Lilly USA, LLC (Eli Lilly and Company), Pfizer Inc, Sun Pharmaceutical Industries Limited, Teva Pharmaceutical Industries Ltd, etc.
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.